Equity Details
Price & Market Data
Price: $2.90
Daily Change: $0.00 / 0.00%
Daily Range: $2.90 - $2.90
Market Cap: $295,113,351
Daily Volume: 100
About Hansa Biopharma AB (publ) (HNSBF)
Stay informed about Hansa Biopharma AB (publ) (HNSBF)'s market activity. The stock is holding at 2.90, showing a daily change of $0.00 / 0.00%. Its market capitalization reaches 295,113,351. Performance metrics include YTD (N/A) and various other periods like 1-week and 6-month returns.
Company Details
Employees: 125
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Sweden
Details
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD) and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was formerly known as Hansa Medical AB (publ) and changed its name to Hansa Biopharma AB (publ) in December 2018. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.